Twenty-one patients identified, six enrolled: that is the early count for Sutter Health’s new biobank registry for LATE, a dementia that mimics Alzheimer’s but has a different cause.
Dr. Shawn Kile presents the registry’s first findings in Boston on Tuesday at the Clinical Trials on Alzheimer’s Disease conference.
Sutter Health researchers in California have opened the LATE Biobank Registry to collect blood, cerebrospinal fluid and clinical data from patients who meet clinical criteria for limbic-predominant age-related TDP-43 encephalopathy — LATE for short. The aim is to understand the disease, develop and validate biomarkers, and build a cohort for future clinical trials.
The stakes rest on one autopsy figure. LATE pathology shows up in roughly 40% of people age 80 and older, Kile said, yet the disease has no specific biomarkers and no known treatments. Memory clinics are now identifying patients whose decline looks like Alzheimer’s but whose tests are negative for amyloid and tau — the proteins that define Alzheimer’s biology — leaving those patients without a precise diagnosis.
“Based on autopsy studies, we are learning that LATE pathology is showing up in approximately 40% of people age 80 and older. This is significant. Whether this is the primary driver of cognitive decline in some cases or co-pathology in other cases, it is important to understand,” said Dr. Kile.
- LATE is a distinct dementia, not a variant of Alzheimer’s. It is caused by an abnormal buildup of the protein TDP-43 in memory-critical brain regions.
- Nobody currently has a routine blood or spinal-fluid test for LATE. A negative Alzheimer’s biomarker test may mean more testing or referral to a specialty memory center is warranted.
- There are no approved LATE-specific treatments yet; registries like this one are the groundwork trials will need.
Biobank Links Samples with Clinical Data over Time
A biobank registry links biological samples — blood and cerebrospinal fluid, the fluid surrounding the brain and spinal cord — with rich clinical data from patients’ ongoing care. Samples are collected over the course of treatment, so researchers can track changes in the same patients over time rather than relying on single snapshots.

The timing follows a shift in the field. The Alzheimer’s Association released clinical criteria for LATE in 2025, and as biomarker testing makes Alzheimer’s easier to identify, neurologists increasingly see Alzheimer’s-like decline in patients who test negative for amyloid and tau. “Some of these patients may instead have LATE,” Kile said.
The reporting frames the registry as a way to address the diagnostic gap: without validated biomarkers, clinicians cannot confirm LATE during life, and the condition has largely been diagnosed after death on autopsy. The registry is designed to move diagnosis from post-mortem to in-life, biomarker-driven practice.
Six Consented, Twenty-One Eligible: The Enrollment Picture
The registry opened for enrollment in May 2026. At the time of abstract submission, researchers had identified 21 patients meeting eligibility criteria, with six consented to participate. Eligible patients can enroll through participating Sutter Health affiliates across California.
Those early numbers are small, and the reports present them as a baseline rather than a result. The value, per the sources, is structural: as enrollment grows, the registry becomes both a biomarker-validation resource and a ready cohort of characterized patients for trials of treatments targeting TDP-43.
How LATE Differs From Alzheimer’s Disease
LATE’s name describes its biology precisely. “Limbic-predominant” marks the brain regions affected — the limbic system, which includes structures critical to memory. “TDP-43” names the protein that abnormally accumulates there. Alzheimer’s, by contrast, is defined by amyloid and tau pathology, which is exactly why biomarker-negative patients raise suspicion for LATE.
| Feature | LATE | Alzheimer’s disease |
|---|---|---|
| Defining protein buildup | TDP-43 | |
| Validated biomarkers | None currently | Amyloid and tau biomarker tests in clinical use |
| Known treatments | None currently | |
| Estimated pathology prevalence | ~40% of people age 80+, on autopsy studies (per Dr. Kile) |
One caution on that 40% figure: it comes from autopsy studies, meaning it describes pathology found after death. Whether LATE is the primary driver of cognitive decline in a given patient, or a co-pathology alongside Alzheimer’s, is precisely what the registry is built to clarify.
What Leaders at Sutter Say It Changes
Greg Tranah, Ph.D., senior scientist and director of the Sutter Biobank, tied the registry to the biobank’s broader purpose of connecting samples with clinical information across the health system, adding that “by building research resources around diseases of aging, we can investigate why people experience conditions such as dementia differently and accelerate the search for biomarkers and more personalized approaches to prevention, diagnosis and treatment.”
Armen Moughamian, M.D., Ph.D., chief of memory for Sutter’s Neuroscience Service Line and medical director of Sutter’s Ray Dolby Brain Health Center at California Pacific Medical Center, described the care-to-research connection as the project’s operating principle.
“That connection between research and real-world care gives us an important opportunity to improve how neurodegenerative diseases such as LATE are recognized and, ultimately, treated,” said Dr. Moughamian.
For patients in California, the practical change is that clinicians at participating Sutter affiliates can now flag clinically suspected LATE cases for enrollment. For patients elsewhere, the report is a signal that memory-clinic evaluation increasingly includes ruling out Alzheimer’s biomarkers before another diagnosis is considered.
What the Reports Do Not Say
No regulatory milestones, such as FDA interaction, are reported, and with no known treatments there is no approved therapy for these patients to access today.
Consult a Physician for Progressive Memory Loss
This is a research registry, not a treatment, so there is no intervention to avoid; enrollment requires informed consent, which means participation is voluntary and can be withdrawn.
What the reporting does support as actionable is diagnostic: anyone with progressive memory loss — particularly adults over 80, the age group where autopsy studies show LATE pathology in approximately 40% of cases — should consult a physician for evaluation, and patients already assessed for Alzheimer’s who tested negative for amyloid and tau biomarkers should ask their clinician whether an alternative diagnosis such as LATE has been considered.
Coverage of cerebrospinal fluid collection is not described in the reports, so enrollees should confirm with the study team what participation involves.
The Question the Registry Cannot Answer Yet
The Tuesday presentation in Boston details how the registry was built and its initial enrollment — not whether any biomarker or treatment works. Shoehorning established therapies into LATE would be premature, since the reports confirm none exist and the biology differs from Alzheimer’s.
The open question, as the reports frame it, is when a biomarker-driven diagnosis of LATE will reach the clinic rather than the morgue. “Ultimately, move toward a biomarker-driven diagnosis and more precise treatments for LATE,” Kile said, is the registry’s stated direction of travel — destination date unstated.
References
- Sutter Health sources and interviews with Dr. Shawn Kile, Greg Tranah, Ph.D., and Armen Moughamian, M.D., Ph.D.
- Alzheimer’s Association: clinical criteria for LATE, released 2025.
- Clinical Trials on Alzheimer’s Disease conference, Boston: abstract “Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Health,” presented November 18.